Korea University Background
When aggravated, non-alcoholic fatty liver disease (NAFLD) develops into non-alcoholic steatohepatitis (NASH) with symptoms such as cirrhosis and fibrosis.
According to a recent report, it has been known that peroxisome proliferator activated receptor(PPAR) γ2 as transcriptional factor is overexpressed and activated in the liver of fatty liver patients.
In addition, the activation of PPARγ2 induces the expression of a variety of target proteins involved in lipid metabolism of the liver.
A pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver:
comprising an inhibitor against 14-3-3βgene
inhibitor comprises an antisense oligonucleotide, siRNA, shRNA or miRNA against the 14-3-3βgene, or a vector comprising the same
inhibitor is an antibody against 14-3-3βprotein
A composition for the diagnosis of non- alcoholic fatty liver:
Comprising a probe for measuring a level of mRNA or a protein of a 14-3-3βgene
The probe for measuring a level of mRNA of the14-3-3βgene is a nucleic acid probe or primer against the mRNA
Effect of 14-3-3β and 14-3-3γ on the expression of PPARγ2 target gene:
It was confirmed that the expression and activation of PPRAγ2 were increased by fatty acid stimulation, and an increased transcriptional activity of PPARγ2 was regulated by 14-3-3β and 14-3-3γ in opposite ways ().
Transcriptional Activity Adjustment of PPAR γ**2**.14-3-3β increases the transcriptional activity ofPPARγ2 by binding to PPARγ2, on the other hand,14-3-3γ plays a role in decreasing the transcriptional activity of PPARγ2.
Use of a target for prevention or treatment of non-alcoholic fatty liver. 4-3-3β and 14-3-3γ as regulating factors ofPPARγ2 are proteins that play a vital role in lipid metabolism.
The technology provides a use for the prevention of non-alcoholic fatty liver, or the development of a therapeutic drug.
This technology can be applied in the field of gene therapy that includes the target gene needed to treat patients, such as non-alcoholic fatty liver treatment or diagnosis.
It is estimated that the NASH treatment market in the seven major countries (US, Germany, France, Italy, Spain, Britain and Japan) will be worth $18 billion in 2026
Estimated CAGR 63.0%
World market size estimated at $25.3 billion in 2026.
: Built in laboratory environment